Erythrocytosis

3 papers1 finding

Associations

1

Gender-affirming hormone therapy

upin humans1

1 study

Gender-affirming hormone therapy is associated with erythrocytosis in humans.
“masculinizing GAHT is associated with adverse lipid changes, erythrocytosis, and a potentially increased risk of major cardiovascular events.”
Reviewmasculinizing GAHT
Cardiovascular health in transgender and gender diverse individuals: an expert opinion on gender-affirming hormone therapy, risk assessment and clinical management
European journal of preventive cardiology11 Oct 2026

More on Gender-affirming hormone therapy

Trial sponsors

University of Colorado, Denver
1 trialPhase 1/285 people

Latest

3 in 12 months

Upsala Journal of Medical SciencesYesterday

De novo development of JAK2V617F-positive polycythemia vera following allogeneic hematopoietic stem cell transplantation: a report of two rare cases

Case seriesBlood and immune system

European Journal of Preventive CardiologyYesterday

Cardiovascular health in transgender and gender diverse individuals: an expert opinion on gender-affirming hormone therapy, risk assessment and clinical management

ReviewCardiovascular disease

European Journal of Clinical Pharmacology13 Aug

SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes

Meta-analysis of studies in peopleSGLT2 inhibitors